Back
ANIX
HealthcareAnixa Biosciences, Inc.
Next Earnings: Q4 2025
Friday, January 9, 2026
Loading...
ANIX EPS History & Predictions
Actual
Consensus
Wall Street
$-0.09consensus
GPT-5.2
$-0.08▲
Gemini 3 Pro
$-0.08▲
Claude-opus
$-0.07▲
GPT-5.2
$-0.08▲
Grok-4
$-0.07▲
Q4 2025 Predictions
AI analyst forecasts for the upcoming earnings release. Click a model to see its reasoning.
GPT-5.2
openrouterEPS
$-0.08
Revenue
$0.00B
Conf.
46%Click for details →
Gemini 3 Pro
openrouterEPS
$-0.08
Revenue
$0.00B
Conf.
90%Click for details →
Claude-opus
openrouterEPS
$-0.07
Revenue
$0.00B
Conf.
72%Click for details →
GPT-5.2
openrouterEPS
$-0.08
Revenue
$0.00B
Conf.
55%Click for details →
Grok-4
openrouterEPS
$-0.07
Revenue
$0.00B
Conf.
80%Click for details →
Predictions Comparison
AI model predictions compared to Wall Street consensus
| Model | EPS Estimate | Revenue Estimate | vs Consensus | Confidence | |
|---|---|---|---|---|---|
GPT-5.2openrouter | $-0.08 | — | -11.1% | 46% | |
Gemini 3 Proopenrouter | $-0.08 | — | -11.1% | 90% | |
Claude-opusopenrouter | $-0.07 | — | -22.2% | 72% | |
GPT-5.2openrouter | $-0.08 | — | -11.1% | 55% | |
Grok-4openrouter | $-0.07 | — | -22.2% | 80% | |
| Wall Street Consensus | $-0.09 | — | — | — |
Wall Street Consensus
Compare AI predictions against Wall Street analyst consensus
Consensus EPS
$-0.10
Last Reported EPS
$-0.07
Last Surprise
30.00%
Report Date
9/10/2025
Quarterly Earnings Surprise Amount
Historical performance vs Wall Street consensus
| Fiscal Quarter End | Date Reported | Earnings Per Share* | Consensus EPS* Forecast | % Surprise |
|---|---|---|---|---|
| Q3 2025 | 9/10/2025 | -0.07 | — | 30.00 |
| Q2 2025 | 5/28/2025 | -0.09 | — | 13.40 |
| Q1 2025 | 3/11/2025 | -0.10 | — | 1.10 |
| Q4 2024 | 1/10/2025 | 0.30 | — | 372.73 |
* EPS values are adjusted for stock splits
Financial Statements
Historical data with AI projections for Q4 2025
All values in Millions (USD) unless otherwise noted
AI Projections | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Line Item | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | GPT-5.2Q4 2025 | Gemini 3 ProQ4 2025 | Claude-opusQ4 2025 | GPT-5.2Q4 2025 | Grok-4Q4 2025 |
| Revenue | |||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Revenue | 0 | 0 | 0.009 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost & Gross Profit | |||||||||
| Gross Profit | 0 | 0 | -0.009 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost And Expenses | 3.16 | 3.39 | 3.00 | 0 | 2.75 | 2.80 | 2.30 | 2.70 | 2.30 |
| Operating Expenses | |||||||||
| Research And Development Expenses | 1.48 | 1.55 | 1.32 | 1.05 | 1.20+13.7% | 1.20 | 1.00-5.2% | 1.20+13.7% | 1.00-5.2% |
| General And Administrative Expenses | 1.69 | 1.83 | 1.68 | 1.38 | 1.55+12.2% | 1.60 | 1.35-2.2% | 1.50+8.6% | 1.30-5.9% |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 1.69 | 1.83 | 1.68 | 1.38 | 1.55+12.2% | 1.60 | 1.35-2.2% | 1.50+8.6% | 1.30-5.9% |
| Other Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 3.16 | 3.39 | 3.00 | 2.44 | 2.75+12.9% | 2.80 | 2.30-5.6% | 2.70+10.8% | 2.30-5.6% |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net | 0.250 | 0.173 | 0.190 | 0 | 0.140 | 0.140 | 0.140 | 0.150 | 0.150 |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | |||||||||
| Net Interest Income | 0.250 | 0.173 | 0.190 | 0.156 | 0.140-10.3% | 0.140 | 0.140-10.3% | 0.150-3.8% | 0.150-3.8% |
| Interest Income | 0.250 | 0.173 | 0.190 | 0.156 | 0.140-10.3% | 0.140 | 0.140-10.3% | 0.150-3.8% | 0.150-3.8% |
| Non Operating Income Excluding Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Adjustments To Net Income | 0.144 | 0.029 | 0 | 0 | 0 | 0 | 0.040 | 0 | 0 |
| Net Income & EPS | |||||||||
| Operating Income | -3.16 | -3.39 | -3.00 | -2.44 | -2.75-12.9% | -2.80 | -2.30+5.6% | -2.70-10.8% | -2.30+5.6% |
| Income Before Tax | -2.91 | -3.21 | -2.81 | 0 | -2.61 | -2.66 | -2.16 | -2.55 | -2.15 |
| Net Income From Continuing Operations | -2.91 | -3.21 | -2.81 | 0 | -2.61 | -2.66 | -2.20 | -2.55 | -2.15 |
| Net Income From Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -2.88 | -3.18 | -2.79 | 0 | -2.61 | -2.66 | -2.20 | -2.55 | -2.15 |
| Net Income Deductions | -12.55 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bottom Line Net Income | 9.67 | -3.18 | -2.79 | 0 | -2.61 | -2.66 | -2.20 | -2.55 | -2.15 |
| Eps | $0.3000 | -$0.0989 | -$0.0866 | -$0.0700 | -$0.0800-14.3% | -$0.0800-14.3% | -$0.0700+0.0% | -$0.0800-14.3% | -$0.0700+0.0% |
| Eps Diluted | 0.30 | -0.10 | -0.09 | -0.07 | -0.08-14.3% | -0.08-14.3% | -0.07+0.0% | -0.08-14.3% | -0.07+0.0% |
| Other | |||||||||
| Filing Date | 0.002 | 0.002 | 0.002 | 0.002 | — | — | — | — | — |
| Fiscal Year | 0.002 | 0.002 | 0.002 | 0.002 | — | — | — | — | — |
| Depreciation And Amortization | 0.009 | 0 | 0.009 | 0 | 0.009 | 0.009 | 0.009 | 0.009 | 0.170 |
| Ebitda | -3.15 | -3.39 | -2.99 | -2.44 | -2.74-12.5% | -2.80 | -2.29+6.0% | -2.69-10.5% | -2.13+12.6% |
| Ebit | -3.16 | -3.39 | -3.00 | 0 | -2.75 | -2.80 | -2.30 | -2.70 | -2.30 |
| Weighted Average Shs Out | 31,898,000 | 32,197,000 | 32,202,000 | 32,476,000 | 32,700,000+0.7% | 32.70 | 33,200,000+2.2% | 32,800,000+1.0% | 32,500,000+0.1% |
| Weighted Average Shs Out Dil | 31,898,000 | 32,197,000 | 32,202,000 | 32,476,000 | 32,700,000+0.7% | 32.70 | 33,200,000+2.2% | 32,800,000+1.0% | 32,500,000+0.1% |